AI assistant
Sending…
Royalty Pharma plc — Director's Dealing 2025
May 9, 2025
30286_dirs_2025-05-09_dc801288-ed1f-4fbc-a547-aa9f007336a5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Royalty Pharma plc (RPRX)
CIK: 0001802768
Period of Report: 2025-05-08
Reporting Person: Coyne Terrance P. (EVP & CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-08 | Class A Ordinary Shares | A | 48646 | — | Acquired | 48646 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Class A Ordinary Shares | 790000 | Indirect |
| Class A Ordinary Shares | 23270 | Indirect |
| Class A Ordinary Shares | 1500 | Direct |
| Class A Ordinary Shares | 24170 | Indirect |
| Class A Ordinary Shares | 1450 | Indirect |
Footnotes
F1: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
More from Royalty Pharma plc
Regulatory Filings
2026
May 28
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Apr 13
Regulatory Filings
2026
Mar 19
Regulatory Filings
2026
Mar 18
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Feb 25
Director's Dealing
2026
Feb 13
Director's Dealing
2026
Feb 13